Daxor (NASDAQ:DXR - Get Free Report)'s stock had its "hold (c-)" rating reissued by stock analysts at
Weiss Ratings in a report released on Wednesday,
Weiss Ratings reports.
Daxor Trading Down 2.8%
Shares of NASDAQ:DXR traded down $0.37 during midday trading on Wednesday, reaching $13.08. 27,140 shares of the company were exchanged, compared to its average volume of 5,259. Daxor has a fifty-two week low of $6.55 and a fifty-two week high of $14.00. The stock has a fifty day simple moving average of $11.40 and a two-hundred day simple moving average of $9.47.
Institutional Investors Weigh In On Daxor
An institutional investor recently bought a new position in Daxor stock. Osaic Holdings Inc. purchased a new stake in Daxor Corporation (NASDAQ:DXR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 8,750 shares of the company's stock, valued at approximately $86,000. Osaic Holdings Inc. owned about 0.18% of Daxor at the end of the most recent quarter. Institutional investors own 1.34% of the company's stock.
Daxor Company Profile
(
Get Free Report)
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Daxor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daxor wasn't on the list.
While Daxor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.